Florence has announced a collaboration with Pfizer to support a global Phase II/III COVID-19 vaccine study. This extensive network of connectivity supports the COVID-19 trial by ensuring research can continue and thrive in a digital capacity, as onsite visits and collaboration are restricted due to the pandemic.

“We’re very proud to work with Pfizer on this vital trial,” says Ryan Jones, CEO of Florence. “It’s meaningful work to be able to support a company that’s at the forefront of innovation for the benefit of the global community. We will continue our support to help ensure Pfizer has everything it needs from a clinical trial software perspective to be successful.”

“Florence’s platform is helping us to respond to the changing environment due to COVID-19 and further progress COVID-19 research with the capability to perform remote monitoring where approved by regulatory authorities and ethics committees,” said Rob Goodwin, Vice President and Head of the Operations Center of Excellence in Global Product Development at Pfizer.